Intestat (Ezetimibe)

Ezetimibe blocks the NPC1L1 transporter in the small intestine, preventing the absorption of dietary and biliary cholesterol. By reducing the amount of cholesterol entering the bloodstream, the liver increases LDL‑receptor activity, leading to greater clearance of LDL cholesterol from the circulation.

The appropriate dose of Intestat is determined by the prescribing healthcare professional based on the patient’s clinical condition, laboratory results, and any concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for ezetimibe in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Intestat product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Intestat (ezetimibe) differs from statins, which inhibit hepatic cholesterol synthesis. Ezetimibe targets intestinal absorption, making it useful as an add‑on therapy when statins alone do not achieve target LDL levels or when statin intolerance occurs. The two classes can be combined for synergistic effect.

Intestat should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Intestat is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events, though rare, include rhabdomyolysis (muscle breakdown), severe liver injury, allergic reactions such as anaphylaxis, and pancreatitis. Patients should seek immediate medical attention if they experience unexplained muscle pain, dark urine, jaundice, severe abdominal pain, or signs of an allergic reaction.

Intestat is contraindicated in patients with known hypersensitivity to ezetimibe or any of its excipients. It should also be avoided in individuals with active liver disease or unexplained persistent elevations in hepatic enzymes. Clinicians must evaluate each patient’s medical history before prescribing.